Revolutionizing diagnostics with rapid, accessible solutions.
Our innovation is a rapid diagnostic device utilizing lateral flow technology. Our device improves accessibility and simplifies testing, especially for infectious diseases. It produces safe, fast, and reliable results that aid critical decision-making in healthcare. This seamless approach revolutionizes the diagnostics landscape.
"Transforming healthcare with rapid, accessible diagnostic solutions for efficient decision-making and better patient outcomes."
Our customers are legal manufacturers who serve the whole testing market in veterinary, human, food safety and environment duagnostics
Time to result, usability pain, less material, everywhere usable, no lab needed, bioplastics, variable modular platform
Lab based diagnostic take days and are expensive. Complex Point-of care devices are also expensive and have target limits. Existing. Rapid testing system generate lots of waste.
With our startup, we are poised to revolutionize the diagnostics space. We offer rapid and easy-to-use solutions that eliminate the need for a lab, drastically reduce testing time, minimize sample material required and utilize eco-friendly bioplastics. What sets us
Our device requires users to simply insert a sample; it auto-analyzes and delivers results in minutes, clearly readable by eye.
We provide manufacturers with fast, sustainable diagnostic solutions for human and animal health as well as environmental and food safety. Our innovative device reduces material usage, eliminates need for labs, and offers a versatile modular platform enhancing decision-making in healthcare.
We estimate the market size for which our solution is designed in monetary terms as follows
Is our goal in the next 3 years
My key role is as a co-inventor and founder, where I am responsible for identifying user needs, establishing functional requirements, and overseeing design and usability based on my medical background.
In addition to Steven, our team could benefit from a business development expert for market expansion and a software engineer for digital solutions.
In the diagnostics space, apart from Senzo's PCR solution for point-of-care testing, we may also face competition from firms offering home-based or digital diagnostic solutions. This could include companies leveraging AI and data-driven approaches to create accurate at-home tests.
Our product leverages analog technology for accurate home and point-of-need testing. It needs no extra devices, infrastructure or training. Designed with simplicity in mind, it operates efficiently even in low-income regions with limited access to lab diagnostics and advanced technologies.
Clients pay for the manufacturing of the patentend device or they buy an oem solution for their certain reagents and test stripes on our platform.
Our startup is making significant strides. We've moved from just an idea to the prototyping stage, rigorously tested our product through clinical studies and received Letters of Intent (LOIs). The customer demand for our solution has been overwhelming.
We are strategically positioned to penetrate the market effectively.
Our startup's key product metric is Lifetime Value (LTV), currently standing at 100,000. This figure reflects the total profit we expect from a customer throughout our relationship, signifying strong consumer loyalty and product satisfaction.
Our current burn rate is $100,000 annually. With this controlled expenditure, our financial runway extends until June 2024—providing ample time to reach profitability and maintain sustainable growth.
Our company incorporated in
Tübingen, germany
Our startup aims to revolutionize healthcare by simplifying diagnostics. However, potential risks include dependency on manufacturers in varied sectors, integration challenges with existing setups, and questions surrounding the long-term sustainability of bioplastics.
$
350000
We raised investments
Angel
$
200000
Currently, we are raising investments
$
1 million
Estimated pre-investment valuation of the company
